HIV will not disappear in a single moment. There is no projected date when the virus will be fully eradicated from the human population. What public health experts are working toward is a more realistic milestone: driving new infections low enough that HIV no longer qualifies as a public health threat. The widely used threshold for that benchmark is fewer than 1 new infection per 1,000 people per year. Some countries could reach that target within the next decade, but globally, the epidemic is still far from over.
What “Ending HIV” Actually Means
When scientists and policymakers talk about ending HIV, they generally mean one of three things, and the distinction matters. The most ambitious goal, a sterilizing cure, would eliminate every trace of the virus from a person’s body. Only three individuals in history are believed to have achieved this, all through extraordinary bone marrow transplant procedures that aren’t scalable to millions of people. A functional cure is more modest: the virus remains in the body but is controlled by the immune system without daily medication, similar to how herpes simplex virus can persist in a dormant state. Many researchers believe a functional cure is more achievable and could eventually be deployed widely. The third definition, and the one most global targets refer to, is epidemiological: reducing new infections and deaths to such low levels that HIV is no longer a major public health crisis.
Where the Global Numbers Stand
New HIV infections have fallen 40% since 2010, dropping from 2.2 million per year to 1.3 million in 2024. That’s genuine progress, but it falls far short of the global target of fewer than 370,000 new infections by 2025. At the current pace, the world is not on track to end HIV as an epidemic anytime soon.
The international framework for measuring progress is built around three benchmarks, known as the 95-95-95 targets: 95% of people living with HIV should know their status, 95% of those diagnosed should be on treatment, and 95% of those on treatment should have the virus suppressed to undetectable levels. Among adults globally, performance sits at roughly 87%, 89%, and 94% for those three targets. That’s close for the third goal but still meaningfully short on the first two, which means hundreds of thousands of people remain undiagnosed or untreated.
The gap is especially stark for children. Only 55% of children living with HIV were on antiretroviral therapy in 2024, compared to 78% of adults. Their progress on the 95-95-95 targets (63%, 87%, 86%) lags behind adults across all three measures.
Regions Where Infections Are Rising
The global average hides a troubling reality: in some parts of the world, the epidemic is getting worse. Eastern Europe and Central Asia have the fastest-growing HIV epidemic on the planet, with 160,000 new infections in 2021, a 48% increase over the prior decade. AIDS-related deaths in the region rose 32% over the same period.
Stigma is a major driver. Gay men and men who have sex with men face intense discrimination in many of these countries, pushing them away from testing and treatment. Migrants from Central Asia working in neighboring countries are disproportionately affected due to poor working conditions and limited access to health services. Harm reduction programs for people who inject drugs cover only about 4% of the population in the region, far below the 50% target. As long as these structural barriers persist, the epidemic will continue expanding in these areas even as it shrinks elsewhere.
Prevention Tools That Could Accelerate the Timeline
The most striking recent development in HIV prevention is a twice-yearly injectable drug called lenacapavir. In a large phase 3 trial involving over 2,100 women, the injection achieved 100% efficacy: zero HIV infections among those who received it. That’s a staggering result, and it addresses one of the biggest challenges in prevention. Daily pills work well in clinical trials, but in real life, people miss doses. A shot every six months removes that barrier almost entirely.
Modeling studies illustrate what’s possible when high-risk populations get consistent access to prevention. One analysis projected that if 50% of young, sexually active, high-risk men who have sex with men in Taiwan received pre-exposure prophylaxis, HIV incidence could fall below the elimination threshold of 1 per 1,000 person-years by 2030. The program would also save money, returning over seven dollars in reduced treatment costs for every dollar spent. The challenge is replicating that kind of coverage in countries with larger, harder-to-reach populations and weaker health infrastructure.
How Close Is a Cure?
Gene-editing technology, particularly CRISPR, represents the most direct attempt at curing HIV. The idea is to cut the virus’s genetic material out of infected cells entirely. In animal studies, researchers have demonstrated that this is possible: the editing tool, delivered via a viral carrier, reached tissues throughout the body including lymph nodes, the central nervous system, and the gut, and successfully snipped out viral DNA.
The first human trial of this approach, a therapy called EBT-101, enrolled six participants with HIV who were already on treatment. The therapy was safe and well tolerated. But when three participants stopped taking their daily antiretroviral medication to test whether the gene editing alone could control the virus, all three experienced viral rebound. A single dose wasn’t enough. The variability in how effectively the editing tool reaches different tissues remains a core challenge. In some animals, viral DNA was successfully cut from lymph nodes and brain tissue but left untouched in the spleen or colon.
An HIV vaccine remains elusive, but mRNA technology has opened new possibilities. A phase 1 trial testing mRNA-encoded HIV proteins found that 80% of participants who received the most promising formulation developed neutralizing antibodies capable of blocking the virus. That’s a meaningful step, though the trial measured immune response rather than real-world protection. Some participants (about 6.5%) developed hives, a higher rate than seen with other mRNA vaccines. A usable vaccine is likely still many years away, but the platform finally shows the kind of immune response that decades of prior vaccine attempts failed to generate.
A Realistic Timeline
Small, well-resourced countries with concentrated epidemics could plausibly reach elimination thresholds within the next five to ten years, particularly if tools like twice-yearly injectable prevention are widely deployed. For much of sub-Saharan Africa, where the majority of people with HIV live, that timeline extends considerably. And in regions like Eastern Europe and Central Asia, where infections are still climbing, the epidemic may worsen before it improves.
A functional cure that allows people to stop daily medication could realistically emerge within the next one to two decades, though “could” is doing heavy lifting in that sentence. A sterilizing cure that completely eliminates HIV from the body remains a far more distant prospect, with no clear timeline. The honest answer is that HIV will end not with a single breakthrough but through the slow, uneven accumulation of better drugs, wider access, reduced stigma, and eventually, curative therapies. For some populations, that process is well underway. For others, it hasn’t meaningfully begun.